Abstract Body

Innovative drugs in the development pipeline for HIV treatment are at a crossroads. The model of introducing drugs with incremental improvements within existing drug classes is now fading. Drugs aimed at novel targets may have a greater impact, especially for providing new options in individuals multi-exposed to ARVs. The scientific community has moved research into combined strategies aiming at long-acting molecules developed with multifacted objectives way beyond the sole control of viral suppression. Novel HIV drugs and combinations are being developed for prevention, treatment, and/or attacking the reservoirs of latent HIV. Continuous investment in novel HIV treatment strategies should be ensured, despite competing priorities, in order to improve the quality of life of affected individuals and to achieve the goal of epidemic control. Public health improvement strategies will require that early on in the development of drugs, diversity is represented at all stages of clinical research.